In our meta-analysis, we found that IL-33 is abnormally expressed in a variety of tumors (such as lung cancer, breast cancer, colorectal cancer, etc.), participates in the occurrence, development and metastasis of tumors and even plays a dual role in promoting tumors and antitumor effects within the same tumor type [13, 62–67]. The gene discussed is IL33; the disease is breast cancer.